Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE + lenvatinib + microwave ablation
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intra-arterial, Interstitial
01
Overview
This combination treatment regimen, investigated in the TALEM trial (NCT05555316) by Sun Yat-sen University Cancer Center, is designed for patients with large unresectable hepatocellular carcinoma (HCC) (≥7 cm). The regimen consists of modified transarterial chemoembolization using blank microspheres with low-dose chemotherapy (BMS-TACE), followed by oral administration of the multi-kinase inhibitor lenvatinib, and sequential radical microwave ablation (MWA) once downstaging is achieved. Lenvatinib targets VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT to inhibit angiogenesis and tumor cell proliferation. The TACE component typically involves lipiodol, low-dose doxorubicin, and lobaplatin. The regimen aims to convert unresectable large tumors into candidates for curative ablation, showing high objective response and downstaging rates in clinical studies.
- Other names
- BMS-TACE + lenvatinib + MWATACE combined with Lenvatinib and MWATACE + lenvatinib-Sun Yat-sen University-hepatocellular carcinoma
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on TACE + lenvatinib + microwave ablation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE + lenvatinib + microwave ablation.